Editas Medicine, Inc. (EDIT)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Editas Medicine, Inc. (EDIT) is up 35.6% since the beginning of the year. At $3 per share, EDIT is trading 38.7% below its 52-week high of $5. Investors who bought $1,000 worth of EDIT shares 5 years ago would now be looking at an investment worth $83.

Editas Medicine, Inc. (EDIT) has returned 35.61% so far this year and 52.75% over the past 12 months. Over the last ten years, EDIT has returned -22.08% per year, falling short of the S&P 500 Index benchmark, which averaged 13.66% annually.

Based on dividend-adjusted daily data since Feb 3, 2016, EDIT's average daily return is +0.07%, while the average monthly return is +1.12%. At this rate, an investment would double in approximately 5.2 years.

Historically, 46% of months were positive and 54% were negative. The best month was Dec 2020 with a return of +129.2%, while the worst month was Dec 2024 at -43.3%. The longest winning streak lasted 9 consecutive months, and the longest losing streak was 6 months.

On a daily basis, EDIT closed higher 48% of trading days. The best single day was Feb 19, 2025 with a return of +83.9%, while the worst single day was Feb 20, 2025 at -35.6%.

Editas Medicine, Inc. has an annualized alpha of -9.15%, beta of 1.75, and R2 of 0.14 versus S&P 500 Index. Calculated based on daily prices since February 04, 2016.

• This stock participated in 217.05% of S&P 500 Index downside but only 125.82% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.14 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

EDIT ranks 60 for risk / return — better than 60% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.

The table below present risk-adjusted performance metrics for Editas Medicine, Inc. (EDIT) and compare them to S&P 500 Index.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Editas Medicine, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Editas Medicine, Inc. was 98.92%, occurring on Apr 8, 2025. The portfolio has not yet recovered.

The current Editas Medicine, Inc. drawdown is 96.93%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Editas Medicine, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Editas Medicine, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.